Biote Corp. Form 8-K Summary
Business Context and Reporting Period
Biote Corp. filed a Current Report on Form 8-K dated July 27, 2022, reporting entry into a material financing agreement and an unregistered equity issuance. The filing does not present quarterly or annual operating results.
Material Financing and Equity Terms
- Biote entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP.
- For 36 months from the agreement date, subject to conditions, Biote may direct Yorkville to purchase shares of Class A common stock from time to time. The facility is optional for Biote; there is no stated obligation to draw funds.
- Each advance will be priced at 97.0% of the lowest daily volume-weighted average price during the three consecutive trading days beginning on the advance notice date.
- Each advance may not exceed the greater of 30% of the prior trading day’s daily volume traded or 1,000,000 shares.
- Total shares issuable under the agreement, including commitment shares, are capped at 5,000,000 shares.
- Biote issued Yorkville 25,000 Class A common shares as commitment fee shares upon execution of the agreement.
- Yorkville’s purchase obligation is subject to conditions, including SEC filing and effectiveness of a registration statement covering resale of the commitment shares and shares issued in advances.
- The commitment shares were issued in reliance on the Securities Act Section 4(a)(2) registration exemption, based on Yorkville’s representations that it is an accredited investor and qualified institutional buyer.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity measures, or historical financial comparisons. The agreement provides potential access to equity capital but does not specify a committed cash amount or minimum funding obligation by Yorkville.
Changes, Outlook, and Risks
- The material change is the establishment of a potential equity financing facility and issuance of 25,000 commitment shares.
- Future advances could dilute existing shareholders and may be issued at a discount to market prices.
- The facility’s availability depends on satisfaction of contractual conditions, including an effective resale registration statement; the filing does not establish that these conditions had been satisfied as of the report date.
- Because advances are discretionary and subject to share-volume limitations, the filing does not provide a guaranteed amount or timing of funding.
- No management guidance, operating outlook, contingencies, or unusual operating items are disclosed.
Important Facts for Investors to Verify
- Whether the registration statement was filed and declared effective.
- Whether Biote subsequently drew on the facility and the number and price of shares issued.
- The remaining capacity under the 5,000,000-share aggregate limit.
- The potential dilution from the 25,000 commitment shares and any future advances.
- The complete terms, conditions, and omitted schedules in Exhibit 10.1, the Standby Equity Purchase Agreement.